7) Nonetheless, some patients still experience treatment failure due to on-treatment viral breakthrough
or relapse after cessation of therapy, possibly attributed to unknown host and viral factors, such as IFNL3 gene polymorphism.
Even within genotype 1, patients with subtype la infections have experienced a higher rate of drug resistance and viral breakthrough
than subtype lb.
Overall, there were three treatment failures: one each in groups 3 and 4 had viral breakthrough
, and one in group 4 experienced a relapse at week 4.
There were no cases of viral breakthrough
during therapy, and HCV deep se-quencing in a subgroup of patients detected none of the genetic mutations known to be associated with resistance to sofosbuvir.
with non detectable serum HBV DNA levels, HBsAg and HBeAg seroconversion and viral breakthrough
No patient was found to be exhibiting viral breakthrough
during the treatment.
The viral breakthrough
rate through 12 weeks on setrobuvir plus P/R was low in both treatment-naive patients (2.
All patients receiving 4 weeks of treatment with ACH-1625 demonstrated continuous and substantial declines in HCV RNA with no viral breakthrough
during therapy at any of the doses.
One patient experienced a viral breakthrough
(increase by >1 LOG10 from nadir during treatment) and one other experienced a 0.
Both viral breakthrough
and genotypic resistance were significantly less common with telbivudine.
The secondary endpoint of combination therapy was prevention of viral breakthrough
and emergence of resistant-type HBV.
There was no viral breakthrough
during treatment and no post-treatment relapse.